Simulations Plus, Inc. - SLP STOCK NEWS

Simulations Plus (Nasdaq: SLP), a key player in biosimulation software for pharmaceuticals, announced participation in BTIG's MedTech, Digital Health, Life Science and Diagnostic Tools Conference from February 15-17, 2022. CEO Shawn O'Connor will present on February 15 at 3:30 p.m. ET and will be available for one-on-one meetings. Interested parties can view the slide presentation on the investors page post-presentation. For more details on the event, visit BTIG's website.

Simulations Plus (NASDAQ: SLP) announced a new collaboration with a large pharmaceutical company to enhance its GastroPlus® ACAT™ model for better understanding of drug disposition in the gastrointestinal tract. The partnership aims to improve functionalities related to local gut delivery and bolster data handling for drug evaluation. This initiative reflects the company's commitment to advancing drug development processes and solidifying its position in biosimulation.

Simulations Plus has announced a new funded collaboration with a major animal health company to enhance its GastroPlus platform. This partnership aims to validate existing animal physiologically based pharmacokinetic (PBPK) models and introduce new species to the platform. The collaboration will bolster veterinary medicine and food production research, promoting animal welfare and public health. Leaders from Simulations Plus emphasized the significance of this expansion into animal health markets, aiming to develop innovative modeling tools.

Simulations Plus, Inc. (NASDAQ: SLP) announced that CEO Shawn O’Connor will present at the Sidoti Winter Small Cap Investor Conference on January 19–20, 2022. O’Connor's presentation is scheduled for January 19, 2022, at 4:00 p.m. ET. Investors can access a live webcast through the Sidoti website. Simulations Plus, a leader in biosimulation, supports drug discovery and development across the globe.

Simulations Plus, a leading modeling and simulation software provider, reported a 16% increase in total revenue for Q1 FY2022, reaching $12.4 million. Software revenue grew 19% to $7.4 million, constituting 59% of total revenue. Net income rose 22% to $3.0 million, with diluted EPS increasing to $0.15. The company announced a quarterly dividend of $0.06 per share, payable on February 7, 2022. CEO Shawn O’Connor expressed confidence in achieving 10-15% revenue growth guidance for the fiscal year, driven by an organic growth strategy and enhancements in software offerings.

Simulations Plus, Inc. (NASDAQ: SLP) announced an update to its MonolixSuite platform, enhancing PKanalix, Monolix, and Simulx modules. The update includes a new bioequivalence module with a user-friendly graphical interface for managing various study designs. New features such as R functions for reporting, a parent-metabolite library, and faster calculations for complex models have been introduced. These advancements aim to streamline the workflow for pharmacometricians, helping users conduct more efficient data analyses and simulations.

Simulations Plus, Inc. (NASDAQ: SLP) will report its financial results for Q1 FY 2022, ending November 30, 2021, on January 6, 2022, after market close. A conference call is scheduled for the same day at 5:00 PM ET, where all interested individuals can join by registering online or via phone. The company, a leader in simulation software for drug discovery and development, has been serving clients for 25 years, providing solutions to major pharmaceutical and regulatory firms globally. More information will be available on their website.

Simulations Plus has announced an extension of its distributor agreement in Japan with Northern Science Consulting for its Monolix software. This partnership builds on existing agreements for GastroPlus and ADMET Predictor, enhancing the company's presence in the Japanese pharmaceutical market. The collaboration aims to boost awareness of Monolix and strengthen relationships with local businesses and universities, reflecting a growing user community in the region.